Newsletter

Six New Contracts Bring the Total Contracted Membership to More Than 174 Million Members Nationally

(Mailing list information, including unsubscription instructions, is located at the end of this message.)

Response Genetics, Inc. (RGDX)

RGDX reported that it has signed agreements with six additional health plans across 10 states bringing the Company's total national contracted membership to more than 174 million lives.

With these agreements, RGDX is now in-network with a total of thirteen Blue Cross Blue Shield health plans, which brings the total number of "Blues" subscribers with direct access to RGDX to approximately 23 million. Among RGDX's other Blue Cross Blue Shield contracts are Blue Cross and Blue Shield of Illinois, Blue Shield of California and CareFirst BlueCross BlueShield (Maryland, Washington, DC and Northern Virginia).

In addition to its recently launched proprietary ResponseDX: Tissue of Origin(TM) diagnostic test, RGDX's molecular testing primarily focuses on therapy-selection for patients with lung, colon, gastric, melanoma, and thyroid cancers.

RGDX's menu of genomic assays provides treating physicians actionable information on a patient's tumor by predicting which course of therapy will work best for that patient. In this way, RGDX's participation with these Blues plans should improve plan members' access to individually-tailored medicine.

RGDX is a CLIA-certified clinical laboratory focused on the development and sale of molecular diagnostic testing services for cancer.

More about Response Genetics, Inc. (RGDX) at www.responsegenetics.com.

**

Syneron Medical Ltd. (ELOS)

Stretch marks are one of the most common skin disorders, impacting 95% of women during puberty or pregnancy, and can also occur in men and children. Historically difficult to treat, striae occur when the skin is stretched from rapid growth or weight gain, and causes damage to the connective tissue in the dermis.

Acne is a common condition experienced by up to 85% of adolescents and young adults and 5% of older adults. In some patients, the healing process results in permanent, disfiguring scars. Treatments ranged from chemical peels to ablative procedures with long recovery times and risky side effects.

ELOS reported that its proprietary Sublative(TM) technology has received CE Mark indication for the effective treatment of striae (stretch marks) and acne scars.

ELOS' Sublative has been shown to be an effective and safe way to reduce the appearance of stretch marks, acne scars and other skin irregularities in all skin types with minimal side effects, discomfort or downtime.

The unique patented technology uses fractionated bi-polar radiofrequency directed to the skin in the form of a matrix. Due to its unique design, energy is deposited in the skin to initiate a healing response with minimal epidermal disruption. Patients benefit from a comfortable treatment with significant outcomes avoiding the potential complications of more aggressive treatments.

After treatment with ELOS' Sublative, the appearance of stretch marks and acne scars are greatly reduced.

ELOS is a leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint.

More about Syneron Medical Ltd. (ELOS) at www.syneron.com

**

General Disclaimer: This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Statements on this website or newsletter may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company’s future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company’s partners that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, seasonal changes, and other risks detailed from time to time in the Company’s filings with the U.S. Securities and Exchange Commission. The actual results may differ materially from those contained on this website. The Company disclaims any obligation to update any statements in this website. These stock quotes and related data are provided for information purposes only and are not intended for trading purposes. Crown Equity Holdings Inc. will not be liable for any inaccuracies or delays in such data, or for any actions taken in reliance thereon. Potential investors should seek independent information and advice from qualified investment professionals prior to investment. Crown Equity Holdings Inc. provides links to websites operated by third parties. These links may be of interest or of use to you, and are provided for convenience only. You should be aware that in using these links, you are leaving Crown Equity Holdings Inc’s website. Crown Equity Holdings Inc. does not approve or endorse the content, information or materials available on such third party websites. In addition, Crown Equity Holdings Inc. makes no representation regarding, and is not responsible for, the content, information or material available on such websites. If you decide to access such websites or newsletter you do this at your own risk, and Crown Equity Holdings Inc. will not be liable for any loss or damage associated with your use of, or reliance on, the content, information or material available on such website.